Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14969719 | 0.92 | TSHR (0.50) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL20429066 | 0.92 | TSHR (0.44) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL15697261 | 0.89 | TSHR (0.43) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL15697254 | 0.89 | TSHR (0.43) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL22811004 | 0.87 | TSHR (0.40) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL26558796 | 0.87 | TSHR (0.40) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL7754985 | 0.86 | TSHR (0.39) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL437917 | 0.84 | TSHR (0.50) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL13132085 | 0.84 | TSHR (0.50) | TSHRKMT2AMEN1LMNACA12 | |
| SCHEMBL4060095 | 0.83 | TSHR (0.67) | TSHRKMT2AMEN1LMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126567-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-20230323207-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| US-20230323207-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| EP-4008759-A1 | POLYMERISABLE LIQUID CRYSTAL MATERIAL AND POLYMERISED LIQUID CRYSTAL FILM | Merck Patent GmbH (DE) | 2022-06-08 | — | — | EP | disclosed |
| US-20220162504-A1 | Polymerisable Liquid Crystal Material and Polymerised Liquid Crystal Film | MERCK PATENT GMBH (DE) | 2022-05-26 | — | — | US | disclosed |
| US-10913897-B2 | Compounds and liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2021-02-09 | — | — | US | disclosed |
| US-10907100-B2 | Compounds and liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2021-02-02 | — | — | US | disclosed |
| EP-3354709-B1 | COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-09-25 | — | — | EP | disclosed |
| US-20180216005-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | US | disclosed |
| US-20180216006-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | US | disclosed |
| US-20180216006-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | US | disclosed |
| US-20180216005-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-02 | — | — | US | disclosed |
| EP-3354710-A1 | COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | Merck Patent GmbH (DE) | 2018-08-01 | — | — | EP | disclosed |
| US-7094943-B2 | Solution phase biopolymer synthesis | Köster, Hubert (US) | 2006-08-22 | — | — | US | disclosed |
| US-7038103-B2 | Solution phase biopolymer synthesis | HUBERT KOSTER (CH) | 2006-05-02 | — | — | US | disclosed |
| US-20020016451-A1 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | CAPROTEC BIOANALYTICS GMBH (DE) | 2002-02-07 | — | — | US | disclosed |
| US-20020007048-A1 | Solution Phase Biopolymer Synthesis | CAPROTEC BIOANALYTICS GMBH (DE) | 2002-01-17 | — | — | US | disclosed |
| EP-1073668-A2 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | Köster, Hubert (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055718-A2 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | KOESTER HUBERT (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913897-B2 | Compounds and liquid-crystalline medium | VIM, NEFM, AQP1 | TSHR 4296/4885KMT2A 4009/4885MEN1 545/4885 |
| US-10907100-B2 | Compounds and liquid-crystalline medium | VIM, NEFM, AQP1 | TSHR 4035/4885KMT2A 3990/4885MEN1 580/4885 |
| US-20180216006-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | VIM, NEFM, AQP1 | TSHR 4035/4885KMT2A 3990/4885MEN1 580/4885 |
| US-20180216005-A1 | COMPOUNDS AND LIQUID-CRYSTALLINE MEDIUM | VIM, NEFM, AQP1 | TSHR 4296/4885KMT2A 4009/4885MEN1 545/4885 |
| US-20020007048-A1 | Solution Phase Biopolymer Synthesis | RNGTT, SGMS1, SPNS2 | TSHR 4614/4885KMT2A 3438/4885MEN1 2353/4885 |
| US-20020016451-A1 | SOLUTION PHASE BIOPOLYMER SYNTHESIS | RNGTT, SGMS1, SPNS2 | TSHR 4614/4885KMT2A 3438/4885MEN1 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.